Publications

Search our bibliography using the filters on the right-hand side.

Displaying 251 through 300 of 467 publications.

Varas-Lorenzo C, Castellsaque J, Stang MR, Tomas L, Aguado J, Perez-Gutthann S. Positive predictive value of icd-9 codes 410-411 for acute coronary syndromes: saskatchewan hospital automated database. Pharmacoepidemiol Drug Saf. 2008 Aug;17(8):842-52.

Candrilli SD, Kuznik A. The prevalence and overlap of select cardiovascular co-morbidities among US adults with dyslipidemia, by lipid-lowering medication use status. Poster presented at the 2008 Midwest Social and Administrative Pharmacy Conference; July 2008. Previously presented at the Annual Meeting of the American College of Clinical Pharmacy.

Heisler M, Hogan MM, Hofer TP, Schmittdiel JA, Pladevall-Vila M, Kerr EA. When more is not better: treatment intensification among hypertensive patients with poor medication adherence. Circulation. 2008 Jun 3;117(22):2884-92. doi: 10.1161/CIRCULATIONAHA.107.724104

Umscheid CA, Maguire MG, Pines JM, Everett WW, Baren JM, Townsend RR, Mines D, Szyld D, Gross R. Untreated hypertension and the emergency department: a chance to intervene? Acad Emerg Med. 2008 Jun;15(6):529-36. doi: 10.1111/j.1553-2712.2008.00132.x

Tang SS, Candrilli SD, Shi L. Utilization of lipid-lowering therapy in hypertensive patients in the United States. Poster presented at the 2008 AcademyHealth Annual Research Meeting; June 2008.

Candrilli SD, Kuznik A. The prevalence and overlap of select cardiovascular comorbidities among dyslipidemic US adults aged 65 years or older, stratified by lipid-lowering medication use. Poster presented at the 31st Annual Meeting of the Society of General Internal Medicine; April 2008. Pittsburg, PA. [abstract] J Gen Intern Med. 2008 Apr; 23(Supplement 2):419.

Harshman RS, Richerson GT, Hadker N, Greene BL, Brown TM, Foster TS. Impact of a hypertension management/health promotion program on commercial driver's license employees of a self-insured utility company. J Occup Environ Med. 2008 Mar 1;50(3):359-65.

Coffin D, Duval K, Martel S, Granton J, Lefebvre MC, Meads DM, Twiss J, McKenna SP. Adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) into French-Canadian and English-Canadian. Can Respir J. 2008 Mar;15(2):77-83.

Menzin J, Wygant G, Hauch O, Jackel JL, Friedman M. One-year costs of ischemic heart disease among patients with acute coronary syndromes: findings from a multi-employer claims database. Curr Med Res Opin. 2008 Feb;24(2):461-8. doi: 10.1185/030079908X261096 .

Williams RE, Kalilani L, DiBenedetti DB, Zhou X, Granger AL, Fehnel SE, Levine KB, Jordan J, Clark RV. Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. Climacteric. 2008 Jan 1;11(1):32-43.

Adams MR, Anthony MS, Chen H, Clarkson TB. Replacement of dietary soy protein isolate with concentrates of soy 7S or 11S globulin has minimal or no effects on plasma lipoprotein profiles and biomarkers of coronary risk in monkeys. Atherosclerosis. 2008 Jan;196(1):76-80.

Candrilli SD, Kuznik A, Rudolph AE. The prevalence and overlap of select cardiovascular comorbidities among US adults with dyslipidemia, by lipid-lowering medication use. Poster presented at the Annual Meeting of the American College of Clinical Pharmacy; October 2007.

Candrilli SD, Kuznik A, Rudolph AE. The prevalence and overlap of select cardiovascular comorbidities among the US elderly with dyslipidemia, by lipid-lowering medication use. Poster presented at the Annual Meeting of the American College of Clinical Pharmacy; October 2007.

Johannes CB, Seeger JD, Koro CE, Cutone JA, Quinn SG. Response to a comment on 'the risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy'. Pharmacoepidemiol Drug Saf. 2007 Oct 1;16(10):1073-4.

Menzin J, Wygant G, Hauch O, Friedman M, Jackel J. One-year costs of ischemic heart disease among patients with acute coronary syndromes: findings from a multi-employer claims database. Poster presented at the Educational Conference of the Academy of Managed Care Pharmacy; October 2007.

Mines D, Fireman B, Lee J, Go AS. Venlafaxine use was not associated with an increased risk of sudden cardiac death. Presented at the 23rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2007. Quebec City, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2007 Aug; 16(Suppl 2):S7.

Varas-Lorenzo C, Rodriguez LA, Maguire A, Castellsague J, Perez-Gutthann S. Use of oral corticosteroids and the risk of acute myocardial infarction. Atherosclerosis. 2007 Jun;192(2):376-83.

Pladevall-Vila M, Williams LK, Elston Lafata J, Wang M, Campbell J, Yang J, Divine G. Adherence to lipid lowering drugs is associated with ldl-cholesterol goal achievement. Poster presented at the Society for Epidemiological Research; June 2007. [abstract] Am J Epidemiol. 165(Suppl_11):S-11.

Javitt JC, Wolowacz SE, Roskell NS, Maciver F, Pleil A, Zlateva G. Balancing visual acuity benefits with systemic adverse effects in anti-VEGF therapy. Poster presented at the ARVO 9th Annual Meeting; May 2007; May 2007. Fort Lauderdale, FL.

Earnshaw SR, Wilson MR, Joshi AV. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage over a two-year managed care enrollment period. Poster presented at the 2007 ISPOR 12th Annual International Meeting; May 22, 2007. [abstract] Value Health. 2007 May; 10(2):A182. Previously presented at the 2006 International Stroke Conference.

Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. Pharmacoepidemiol Drug Saf. 2007 May 1;16(5):504-12.

Candrilli SD, Lee E, Tang SSK, Bassin S, Laird HJ, Levy SS, Wong ND. Cardiovascular risk in US urban hispanic populations: regional data from community outreach programs. Poster presented at the American College of Cardiology 56th Annual Scientific Session; March 27, 2007.

Tang SSK, Lee E, Candrilli SD, Laird HJ, Levy SS, Bassin S, Wong ND. Prevalence, treatment, and control of hypertension and/or dyslipidemia among hispanic adults in US communities. Poster presented at the American College of Cardiology 56th Annual Scientific Session; March 27, 2007.

Lee E, Tang SSK, Candrilli SD, Bassin S, Laird HJ, Levy SS, Wong ND. Regional differences in the prevalence of hypertension and dyslipidemia in US urban hispanic populations. Poster presented at the American College of Cardiology 56th Annual Scientific Session; March 27, 2007.

Pignone M, Earnshaw S, Pletcher MJ, Tice JA. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis. Arch Intern Med. 2007 Feb 12;167(3):290-5.

Umscheid CA, Maguire MG, Pines JM, Everett WW, Baren JM, Townsend RR, Mines D, Szyld D, Gross R. The prevalence of and risk factors associated with untreated hypertension in ED patients. Poster presented at the 2007 Society for Academic Emergency Medicine Conference; May 2007. Chicago, IL. [abstract] Acad Emerg Med. 2007; 14(5 Suppl 1):S117.

Earnshaw SR, Wilson M, Joshi AV. The effect of recombinant activated factor VII in the treatment of intracerebral hemorrhage on health plan budgets. Managed Care Interface. 2007 Jan 1;19(11):39-45.

Payne JR, James LE, Eleftheriou KI, Hawe E, Mann J, Stronge A, Banham K, World M, Humphries SE, Pennell DJ, Montgomery HE. The association of left ventricular mass with blood pressure, cigarette smoking and alcohol consumption; data from the LARGE Heart study. Int J Cardiol. 2007;120(1):52-8.

Arellano FM, Yood MU, Wentworth CE, Oliveria SA, Rivero E, Verma A, Rothman KJ. Use of Cyclo-Oxygenase 2 Inhibitors (COX-2) and prescription Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile. Pharmacoepidemiol Drug Saf. 2006 Dec 1;15(12):861-72.

Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Stroke. 2006 Nov 28;37(11):2751-8.

Earnshaw SR, Wilson MR, Joshi AV. Budgetary impact analysis of recombinant activated factor vii in the treatment of intracerebral hemorrhage: a US health plan perspective. Poster presented at the 2006 ISPOR 9th Annual European Congress; October 31, 2006. [abstract] Value Health. 2006 Nov; 9(6):A329.

Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage. Poster presented at the 2006 International Stroke Conference; February 17, 2006. [abstract] Stroke. 2006 Nov; 37(11):2751.

Earnshaw SR, Pignone M, Tice J, Pletcher M. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Poster presented at the Annual Meeting of the Institute for Operations Research and the Management Sciences; November 2006.

Appt SE, Clarkson TB, Lees CJ, Anthony MS. Low dose estrogens inhibit coronary artery atherosclerosis in postmenopausal monkeys. Maturitas. 2006 Sep 20;55(2):187-94.

Varas-Lorenzo C, McQuay L, Eaton S, Saez-Lloret I, Melero-Montes M, Miller D, Perez-Gutthann S. Characterization of US adult users of antihypertensive medications. Poster presented at the 22nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2006. Lisbon, Portugal.

Varas-Lorenzo C, Maguire A, Castellsague J, Perez-Gutthann S. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level. Poster presented at the 22nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2006. Lisbon, Portugal. [abstract] Pharmacoepidemiol Drug Saf. 2006 Aug; 15(S1):S243.

Varas-Lorenzo C, Stang MR, Tomas L, Gimeno V, Castellsague J, Perez-Gutthann S. Positive predictive value of ICD-9 Code 411 in the identification of cases of acute coronary syndrome in the Saskatchewan Hospital Database. Poster presented at the 22nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2006. Lisbon, Portugal. [abstract] Pharmacoepidemiol Drug Saf. 2006 Aug; 15(S1):S231.

Tunceli K, Pladevall-Vila M, Williams LK, Divine GW, Simpkins JC, Nag SS, Sajjan SG, Kamal-Bahl SJ, Alexander CM, Lafata JE. Trends in lipid management among patients with diabetes. Endocr Pract. 2006 Jul;12(4):380-7.

Candrilli S, Mackell J. Effect of ncep atp iii guideline revisions on the prevalence of dyslipidemia among the elderly: evidence from nhanes. Poster presented at the 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke; May 9, 2006.

Earnshaw SR, Wilson MR, Joshi AV. Short-term cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Value Health. 2006 May 1;9(3):A8.

Earnshaw SR, Joshi AV, Wilson MR. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage: a US managed care perspective. Poster presented at the Academy of Managed Care Pharmacy 18th Annual Meeting; April 7, 2006.

Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med. 2006 Mar 7;144(5):326-36.

McKenna SP, Doughty N, Meads DM, Doward LC, Pepke-Zaba J. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res. 2006 Feb 1;15(1):103-15.

Earnshaw SR, Wilson MR, Joshi AV. Health plan budget impact analysis of recombinant activated factor VII (rFVIIa) in the treatment of intracerebral hemorrhage. Managed Care Interface. 2006;19(11):39-45.

Brodtkorb T. Plötslig hjärtdöd bland barn, ungdomar och unga vuxna vid idrott och fysisk ansträngning: komplettering av Socialstyrelsens riktlinjer för hjärtsjukvård 2004. 2006.

Payne JR, Eleftheriou KI, James LE, Hawe E, Mann J, Stronge A, Kotwinski P, World M, Humphries SE, Pennell DJ, Montgomery HE. Left ventricular growth response to exercise and cigarette smoking: data from LARGE Heart. Heart. 2006;92(12):1784-8.

Casas JP, Shah T, Cooper J, Hawe E, McMahon AD, Gaffney D, Packard CJ, O'Reilly DS, Juhan-Vague I, Yudkin JS, Tremoli E, Margaglione M, Di Minno G, Hamsten A, Kooistra T, Stephens JW, Hurel SJ, Livingstone S, Colhoun HM, Miller GJ, Bautista LE, Meade T, Sattar N, Humphries SE, Hingorani AD. Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol. 2006;35(4):922-31.

Humphries SE, Cranston T, Allen M, Middleton-Price H, Fernandez MC, Senior V, Hawe E, Iversen A, Wray R, Crook MA, Wierzbicki AS. Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing. J Mol Med (Berl). 2006;84(3):203-14.

Pignone M, Earnshaw SR. Cost-effectiveness of aspirin for the primary prevention of cardiovascular events in women. Poster presented at the Society of Medical Decision Making; October 2005.